Cargando…

Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity

Glioblastoma, one of the most aggressive primary brain tumors, is characterized by highly immunosuppressive microenvironment. This contributes to glioblastoma resistance to standard treatment modalities and allows tumor growth and recurrence. Several immune-targeted approaches have been recently dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angelova, Assia L., Barf, Milena, Geletneky, Karsten, Unterberg, Andreas, Rommelaere, Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744156/ https://www.ncbi.nlm.nih.gov/pubmed/29244745 http://dx.doi.org/10.3390/v9120382

Ejemplares similares

Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients
por: Angelova, Assia L., et al.
Publicado: (2015)

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
por: Geletneky, Karsten, et al.
Publicado: (2017)

Oncolytic parvoviruses: from basic virology to clinical applications
por: Marchini, Antonio, et al.
Publicado: (2015)

Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
por: Marchini, Antonio, et al.
Publicado: (2019)

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2014)

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
por: Angelova, Assia L., et al.
Publicado: (2017)

Improved Killing of Human High-Grade Glioma Cells by Combining Ionizing Radiation with Oncolytic Parvovirus H-1 Infection
por: Geletneky, Karsten, et al.
Publicado: (2010)

Immune System Stimulation by Oncolytic Rodent Protoparvoviruses
por: Angelova, Assia, et al.
Publicado: (2019)

Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers
por: Angelova, Assia, et al.
Publicado: (2021)

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol
por: Geletneky, Karsten, et al.
Publicado: (2012)

Generation and Validation of Monoclonal Antibodies Suitable for Detecting and Monitoring Parvovirus Infections
por: Tessmer, Claudia, et al.
Publicado: (2022)

A novel scalable, robust downstream process for oncolytic rat parvovirus: isoelectric point-based elimination of empty particles
por: Leuchs, Barbara, et al.
Publicado: (2017)

Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2011)

Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy
por: Qi, Zhongbing, et al.
Publicado: (2022)

Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells
por: Angelova, Assia, et al.
Publicado: (2023)

Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis
por: Lacroix, Jeannine, et al.
Publicado: (2014)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Activation of a Helper and Not Regulatory Human CD4+ T Cell Response by Oncolytic H-1 Parvovirus
por: Moralès, Olivier, et al.
Publicado: (2012)

Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro
por: Geiss, Carsten, et al.
Publicado: (2017)

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
por: Meyers, Daniel E., et al.
Publicado: (2017)

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
por: Meyers, Daniel E., et al.
Publicado: (2017)

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
por: Pombo Antunes, Ana Rita, et al.
Publicado: (2020)

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022)

Immunotherapeutic Advancements for Glioblastoma
por: Ampie, Leonel, et al.
Publicado: (2015)

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors
por: Gibson, Heather, et al.
Publicado: (2015)

Correction: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
Publicado: (2022)

Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis
por: Ferreira, Tiago, et al.
Publicado: (2020)

Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas
por: Li, Junwei, et al.
Publicado: (2013)

Parvoviruses-tools to fine-tune anticancer immune responses
por: Grekova, Svitlana P., et al.
Publicado: (2012)

Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo
por: Lacroix, Jeannine, et al.
Publicado: (2018)

Portrait of a Leader in Immunotherapeutics: Oncolytic viruses for treatment of cancer
por: Hemminki, Akseli
Publicado: (2012)

New Immunotherapeutic Approaches for Glioblastoma
por: Vázquez Cervantes, Gustavo Ignacio, et al.
Publicado: (2021)

Immunotherapeutic Approaches for Glioblastoma Treatment
por: Yaghi, Nasser K., et al.
Publicado: (2022)

Emerging role of Natural killer cells in oncolytic virotherapy
por: Bhat, Rauf, et al.
Publicado: (2015)

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
por: Breitbach, Caroline J, et al.
Publicado: (2015)

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
por: Ricca, Jacob M., et al.
Publicado: (2018)

Safety study supports clinical development of immunotherapeutic oncolytic measles vaccine
por: Engeland, Christine E.
Publicado: (2022)

Current Immunotherapeutic Strategies for the Treatment of Glioblastoma
por: Dapash, Mark, et al.
Publicado: (2021)

Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations
por: Niedbała, Marcin, et al.
Publicado: (2022)

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol
por: Hajda, Jacek, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nkipvnmq6fhfcflrj3umruim20